Stock LFCR LIFECORE BIOMEDICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lifecore Biomedical, Inc.

Equities

LFCR

US5147661046

Market Closed - Nasdaq
Other stock markets
 01:30:00 02/05/2024 am IST 		5-day change 1st Jan Change
6.44 USD +0.31% Intraday chart for Lifecore Biomedical, Inc. +1.74% +4.04%
19/04 Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report MT
01/04 Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 CI

Evolution of the average Target Price on Lifecore Biomedical, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5607989391310b.zaho5PbFgjeUhHw5O_oUVmzeI0MgYcaSG8u0Rqw8v3A.odAxnoGs1nGnxzdwXbJDPjPpTjtRMrLUao35Adhd9gOFyQWioJXvY6PPTA~7cb0a501563105867eb318f6c1ce2b8e

Analyst Recommendations on Lifecore Biomedical, Inc.

Stephens Adjusts Price Target on Lifecore Biomedical to $9 From $8, Maintains Equalweight Rating MT
Barrington Trims Price Target on Lifecore Biomedical to $10 From $11, Maintains Outperform Rating MT
Barrington Raises Price Target on Lifecore Biomedical to $11 From $10, Keeps Outperform Rating MT
Barrington Cuts Price Target on Lifecore Biomedical to $8 From $10, Keeps Outperform Rating MT
Barrington Research Lowers Landec's Price Target to $12 From $14, Maintains Outperform Rating MT
Barrington Research Upgrades Landec to Outperform From Market Perform, Sets $14 Price Target MT
Stephens Starts Landec at Overweight With $13 Price Target MT
Barrington Research Downgrades Landec to Market Perform From Outperform MT
LANDEC : Roth Capital Adjusts Landec's Price Target to $14 from $15, Keeps Buy Rating MT
LANDEC : Barrington Adjusts Price Target on Landec to $12 From $14 After 'Mixed Bag Q1 Result', Maintains Outperform Rating MT
LANDEC : Barrington Upgrades Landec to Outperform From Market Perform Following Windset Unit Sale, Sets $13 Price Target MT
LANDEC : Roth Capital Adjusts Landec PT to $12 From $15, Maintains Buy Rating MT
LANDEC : Lake Street Adjusts Landec's Price Target to $12 From $13, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.44 USD
Average target price
6 USD
Spread / Average Target
-6.83%
High Price Target
6 USD
Spread / Highest target
-6.83%
Low Price Target
6 USD
Spread / Lowest Target
-6.83%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lifecore Biomedical, Inc.

Stephens Inc.
Barrington Research
Roth Capital Partners
Lake Street

Ratings for Lifecore Biomedical, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LFCR Stock
  4. Consensus Lifecore Biomedical, Inc.